{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:07:53Z","timestamp":1772168873169,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.150723.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000}},{"DOI":"10.12688\/f1000research.150723.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000}}],"reference-count":123,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universidad Catolica de Santa Maria","award":["grants 27574-R-2020, 28048-R-2021"],"award-info":[{"award-number":["grants 27574-R-2020, 28048-R-2021"]}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns5:p>Background Chagas disease (CD) is a neglected tropical disease endemic to Latin America, has emerged as a global health concern due to the migration of infected individuals. With its epidemiological complexity, by difficulty to obtain appropriate diagnoses and poor treatment, the search for novel therapeutic options remains. Methods In this context, we conducted a systematic review and meta-analysis of preclinical studies employing animal models to verify the progress in CD treatment. We searched the PubMed database for CD treatment studies published between 1990 and 2023, adhering to the PRISMA guidelines. Results Twelve papers met the inclusion criteria. The findings indicate that the fifteen treatment alternatives examined, mainly between 2010 and 2014, demonstrated efficacy in experimental CD models, evidenced by significant parasitemia reduction. Bis-triazole DO870 and VNI were effective in the acute and chronic phases, respectively. However, of these emerging therapies, only posaconazole and fexinidazole have progressed to clinical trials, yielding unsatisfactory outcomes as CD monotherapies Conclusions This meta-analysis highlights the existence of promising new drug candidates for CD treatment, but most remain in the preclinical stages. Those that reached clinical trials did not demonstrate optimal results, underscoring the ongoing challenges in CD therapy. Collaborative efforts among the academic community, pharmaceutical industries, funding agencies, and government agencies are urgently needed to accelerate the development of more effective medications against CD. Inplasy registration INPLASY202430101 (25\/03\/2024)<\/ns5:p>","DOI":"10.12688\/f1000research.150723.3","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:30:09Z","timestamp":1747373409000},"page":"885","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment options applied to the preclinical studies using animal models for Chagas Disease: a systematic review and meta-analysis"],"prefix":"10.12688","volume":"13","author":[{"given":"Laura Yesenia","family":"Machaca-Luque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-3840","authenticated-orcid":false,"given":"Mayron Antonio","family":"Candia-Puma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brychs Milagros","family":"Roque-Pumahuanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8791-0506","authenticated-orcid":false,"given":"Haruna Luz","family":"Barazorda-Ccahuana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-1160","authenticated-orcid":false,"given":"Luis Daniel","family":"Goyzueta-Mamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexsandro","family":"Sobreira Galdino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Andrez","family":"Machado-de-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo Cordeiro","family":"Cordeiro Giunchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Antonio","family":"Ferraz Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-4802","authenticated-orcid":false,"given":"Miguel Angel","family":"Chavez-Fumagalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"10-11","DOI":"10.1051\/parasite\/2014012","article-title":"Chagas disease in the 21st Century: a public health success or an emerging threat?","volume":"21","author":"K Bonney","year":"2014 Mar 10","journal-title":"Parasite."},{"key":"ref2","article-title":"Chagas\u2019 Disease (American Trypanosomiasis) Fact Sheet.","year":"2023 cited 2024 Feb 23"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"949-979","DOI":"10.1128\/CMR.00045-14","article-title":"Emerging and Reemerging Neglected Tropical Diseases: a Review of Key Characteristics, Risk Factors, and the Policy and Innovation Environment.","volume":"27","author":"T Mackey","year":"2014 Oct","journal-title":"Clin. Microbiol. Rev."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"25-40","DOI":"10.2147\/RRTM.S278135","article-title":"Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas.","volume":"13","author":"C Su\u00e1rez","year":"2022 Jul","journal-title":"Res. Rep. Trop. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100507","DOI":"10.1016\/j.cpcardiol.2019.100507","article-title":"Chagas Disease: Chronic Chagas Cardiomyopathy.","volume":"46","author":"N Echavarr\u00eda","year":"2021 Mar","journal-title":"Curr. Probl. Cardiol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0007937","DOI":"10.1371\/journal.pntd.0007937","article-title":"The role of the first level of health care in the approach to Chagas disease in a non-endemic country.","volume":"13","author":"L Iglesias-Rus","year":"2019 Dec 16","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"35-44","DOI":"10.1007\/s00436-016-5291-z","article-title":"Overcoming research barriers in Chagas disease\u2014designing effective implementation science.","volume":"116","author":"A Henao-Mart\u00ednez","year":"2017 Jan 22","journal-title":"Parasitol. Res."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"145-158","DOI":"10.1080\/17460441.2020.1681394","article-title":"Why hasn\u2019t there been more progress in new Chagas disease drug discovery?","volume":"15","author":"A Vermelho","year":"2020 Feb 1","journal-title":"Expert Opin. Drug Discov."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7-17","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current trends in the pharmacological management of Chagas disease.","volume":"12","author":"V Ribeiro","year":"2020 Apr","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1-16","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas disease.","volume":"156","author":"J Bermudez","year":"2016 Apr","journal-title":"Acta Trop."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"102972","DOI":"10.1016\/j.eclinm.2024.102972","article-title":"Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.","volume":"79","author":"A Rassi","year":"2025 Jan","journal-title":"eClinicalMedicine."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"32457849","DOI":"10.3389\/fcimb.2020.00210","article-title":"Precision Health for Chagas Disease: Integrating Parasite and Host Factors to Predict Outcome of Infection and Response to Therapy.","volume":"10","author":"S Martinez","year":"2020 May 8","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e0006989","DOI":"10.1371\/journal.pntd.0006989","article-title":"Strategies to increase adoption of animal vaccines by smallholder farmers with focus on neglected diseases and marginalized populations.","volume":"13","author":"M Donadeu","year":"2019 Feb 7","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01929\/full","article-title":"The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.","volume":"9","author":"G Acevedo","year":"2018 Aug 24","journal-title":"Front. Immunol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40249-018-0444-1","article-title":"Innovation in neglected tropical disease drug discovery and development.","volume":"7","author":"H Weng","year":"2018 Dec 18","journal-title":"Infect. Dis. Poverty."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5334\/gh.484\/","article-title":"WHF IASC Roadmap on Chagas Disease.","volume":"15","author":"L Echeverr\u00eda","year":"2020 Mar 30","journal-title":"Glob. Heart."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1381-1402","DOI":"10.1080\/17460441.2020.1806233","article-title":"Animal models of Chagas disease and their translational value to drug development.","volume":"15","author":"E Chatelain","year":"2020 Dec 1","journal-title":"Expert Opin. Drug Discov."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"947-959","DOI":"10.1080\/13543784.2020.1793955","article-title":"Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?","volume":"29","author":"N Mart\u00ednez-Peinado","year":"2020 Sep 1","journal-title":"Expert Opin. Investig. Drugs."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"112020","DOI":"10.1016\/j.biopha.2021.112020","article-title":"Advances in the treatment of Chagas disease: Promising new drugs, plants and targets.","volume":"142","author":"P Garc\u00eda-Huertas","year":"2021 Oct","journal-title":"Biomed. Pharmacother."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-00054-7_16","author":"E Ruiz-Lancheros","year":"2019","journal-title":"Chagas Disease: A Clinical Approach."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"M Page","year":"2021 Mar 29","journal-title":"BMJ."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1053-1070","DOI":"10.1007\/s11192-017-2300-7","article-title":"Citation-based clustering of publications using CitNetExplorer and VOSviewer.","volume":"111","author":"N Eck","year":"2017 May 27","journal-title":"Scientometrics."},{"key":"ref23","article-title":"Treatment Outcome. MeSH Terms.","year":"1992 cited 2024 Feb 28"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"323-339","DOI":"10.1177\/0145445516673998","article-title":"Intercoder Reliability and Validity of WebPlotDigitizer in Extracting Graphed Data.","volume":"41","author":"D Drevon","year":"2017 Mar 22","journal-title":"Behav. Modif."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"553-561","DOI":"10.1016\/j.jshs.2020.02.003","article-title":"Effect of citrulline on post-exercise rating of perceived exertion, muscle soreness, and blood lactate levels: A systematic review and meta-analysis.","volume":"9","author":"H Rhim","year":"2020 Dec","journal-title":"J. Sport Health Sci."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.vesic.2022.100009","article-title":"Extracellular vesicle therapy for non-ischemic heart failure: A systematic review of preclinical studies.","volume":"1","author":"R Vaka","year":"2022 Dec","journal-title":"Extracell. Vesicle."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e0199041","DOI":"10.1371\/journal.pone.0199041","article-title":"The anxiolytic effect of probiotics: A systematic review and meta-analysis of the clinical and preclinical literature.","volume":"13","author":"D Reis","year":"2018 Jun 20","journal-title":"PLoS One."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies.","volume":"14","author":"C Hooijmans","year":"2014 Dec 26","journal-title":"BMC Med. Res. Methodol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"924-926","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"G Guyatt","year":"2008 Apr 26","journal-title":"BMJ."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1-48","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package.","volume":"36","author":"W Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"206-242","DOI":"10.3102\/1076998616674315","article-title":"A Review of Meta-Analysis Packages in R.","volume":"42","author":"J Polanin","year":"2017 Apr 30","journal-title":"J. Educ. Behav. Stat."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"97-111","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis.","volume":"1","author":"M Borenstein","year":"2010 Apr","journal-title":"Res. Synth. Methods."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"646-652","DOI":"10.1177\/1474515120944014","article-title":"Meta-analysis: How to quantify and explain heterogeneity?","volume":"19","author":"T Ruppar","year":"2020 Oct 5","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses.","volume":"15","author":"P Hippel","year":"2015 Dec 14","journal-title":"BMC Med. Res. Methodol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"685-695","DOI":"10.1007\/s00184-017-0622-3","article-title":"Some general points on the I2-measure of heterogeneity in meta-analysis.","volume":"80","author":"D B\u00f6hning","year":"2017 Nov 22","journal-title":"Metrika."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"354-368","DOI":"10.1002\/jrsm.1678","article-title":"Avoiding common mistakes in meta-analysis: Understanding the distinct roles of Q, I-squared, tau-squared, and the prediction interval in reporting heterogeneity.","volume":"15","author":"M Borenstein","year":"2023 Nov 8","journal-title":"Res. Synth. Methods."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"557-560","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"J Higgins","year":"2003 Sep 6","journal-title":"BMJ."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3147-3152","DOI":"10.1007\/s11255-023-03626-w","article-title":"Measures of frequency and effect in clinical research.","volume":"55","author":"G D\u2019Arrigo","year":"2023 May 10","journal-title":"Int. Urol. Nephrol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e857-e861","DOI":"10.4088\/JCP.15f10150","article-title":"Understanding Relative Risk, Odds Ratio, and Related Terms: As Simple as It Can Get.","volume":"76","author":"C Andrade","year":"2015 Jul 22","journal-title":"J. Clin. Psychiatry."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"527-532","DOI":"10.1016\/j.ijantimicag.2012.08.002","article-title":"Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome\u00ae in mice infected with Trypanosoma cruzi strains.","volume":"40","author":"S Cencig","year":"2012 Dec","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e2367","DOI":"10.1371\/journal.pntd.0002367","article-title":"Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments.","volume":"7","author":"L Diniz","year":"2013 Aug 15","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"101-104","DOI":"10.1093\/jac\/47.1.101","article-title":"Cure of experimental Chagas\u2019 disease by the bis-triazole DO870 incorporated into \u201cstealth\u201d polyethyleneglycol-polylactide nanospheres.","volume":"47","author":"J Molina","year":"2001 Jan 1","journal-title":"J. Antimicrob. Chemother."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1167-1178","DOI":"10.1128\/AAC.01855-13","article-title":"Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure.","volume":"58","author":"M Ndao","year":"2014 Feb","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"3318-3325","DOI":"10.1128\/AAC.00323-10","article-title":"In Vitro and in vivo Trypanocidal Effects of the Cyclopalladated Compound 7a, a Drug Candidate for Treatment of Chagas\u2019 Disease.","volume":"54","author":"A Matsuo","year":"2010 Aug","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: A Potential New Drug Candidate for Chagas Disease.","volume":"6","author":"M Bahia","year":"2012 Nov 1","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"5307-5314","DOI":"10.1128\/AAC.00595-13","article-title":"Activities of Psilostachyin A and Cynaropicrin against Trypanosoma cruzi in vitro and In Vivo.","volume":"57","author":"C Silva","year":"2013 Nov","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"980-986","DOI":"10.1016\/j.imbio.2009.11.002","article-title":"Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.","volume":"215","author":"C Santos","year":"2010 Dec","journal-title":"Immunobiology."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"504-511","DOI":"10.1093\/infdis\/jit042","article-title":"VNI Cures Acute and Chronic Experimental Chagas Disease.","volume":"208","author":"F Villalta","year":"2013 Aug 1","journal-title":"J. Infect. Dis."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"703-708","DOI":"10.1007\/s00436-010-1725-1","article-title":"(\u2212)\u2212Hinokinin-loaded poly(d,l-lactide-co-glycolide) microparticles for Chagas disease.","volume":"106","author":"J Saraiva","year":"2010 Feb 28","journal-title":"Parasitol. Res."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1279-1283","DOI":"10.1007\/s00436-010-2002-z","article-title":"Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi.","volume":"107","author":"P Gobbi","year":"2010 Oct 3","journal-title":"Parasitol. Res."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e1696","DOI":"10.1371\/journal.pntd.0001696","article-title":"Oral Administration of GW788388, an Inhibitor of Transforming Growth Factor Beta Signaling, Prevents Heart Fibrosis in Chagas Disease.","volume":"6","author":"F Oliveira","year":"2012 Jun 12","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"46-53","DOI":"10.1128\/IAI.72.1.46-53.2004","article-title":"Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice.","volume":"72","author":"E Dumonteil","year":"2004 Jan","journal-title":"Infect. Immun."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41419-017-0059-7","article-title":"Cell death-based treatments of melanoma: conventional treatments and new therapeutic strategies.","volume":"9","author":"G Mattia","year":"2018 Jan 25","journal-title":"Cell Death Dis."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e1009254","DOI":"10.1371\/journal.ppat.1009254","article-title":"Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease.","volume":"17","author":"W Wang","year":"2021 Jan 28","journal-title":"PLoS Pathog."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"225-252","DOI":"10.1002\/ddr.21664","article-title":"The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets.","volume":"83","author":"F Altamura","year":"2022 Apr 6","journal-title":"Drug Dev. Res."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"38-52","DOI":"10.1016\/j.actatropica.2017.09.017","article-title":"Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity.","volume":"184","author":"B Zingales","year":"2018 Aug","journal-title":"Acta Trop."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e2488","DOI":"10.1371\/journal.pntd.0002488","article-title":"Barriers to Treatment Access for Chagas Disease in Mexico.","volume":"7","author":"J Manne","year":"2013 Oct 17","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"108-113","DOI":"10.4269\/ajtmh.14-0826","article-title":"Access to Care for Chagas Disease in the United States: A Health Systems Analysis.","volume":"93","author":"V Wirtz","year":"2015 Jul 8","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1262-1265","DOI":"10.1016\/j.amjmed.2020.05.022","article-title":"Chagas Disease: Epidemiology and Barriers to Treatment.","volume":"133","author":"R Mills","year":"2020 Nov","journal-title":"Am. J. Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"135-185","DOI":"10.5840\/bpej20123116","article-title":"Poverty, Disease, and Medicines in Low- and Middle-Income Countries.","volume":"31","author":"K Leisinger","year":"2012","journal-title":"Bus. Prof. Ethics J."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e3379","DOI":"10.1371\/journal.pntd.0003379","article-title":"A Changing Model for Developing Health Products for Poverty-Related Infectious Diseases.","volume":"9","author":"P Olliaro","year":"2015 Jan 8","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2830-2843","DOI":"10.1021\/acsinfecdis.0c00353","article-title":"Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge.","volume":"6","author":"J Mart\u00edn-Escolano","year":"2020 Nov 13","journal-title":"ACS Infect. Dis."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"22-35","DOI":"10.1177\/1087057114550585","article-title":"Chagas Disease Drug Discovery: Toward a New Era.","volume":"20","author":"E Chatelain","year":"2015 Jan","journal-title":"SLAS Discov."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"582-592","DOI":"10.1021\/acsinfecdis.2c00569","article-title":"Genetic Characterization of Trypanosoma cruzi I Populations from an Oral Chagas Disease Outbreak in Venezuela: Natural Resistance to Nitroheterocyclic Drugs.","volume":"9","author":"A Mu\u00f1oz-Calder\u00f3n","year":"2023 Mar 10","journal-title":"ACS Infect. Dis."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"03002","DOI":"10.7189\/jogh.15.03002","article-title":"AI-powered drug discovery for neglected diseases: accelerating public health solutions in the developing world.","volume":"15","author":"M Nishan","year":"2025 Jan 10","journal-title":"J. Glob. Health."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"287-308","DOI":"10.1007\/978-3-031-82622-1_12","author":"M Ogwu","year":"2025","journal-title":"Emerging Trends in Tropical Medicine."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1373-1384","DOI":"10.1111\/tmi.13478","article-title":"Neglected tropical diseases in Brazil: lack of correlation between disease burden, research funding and output.","volume":"25","author":"B Fonseca","year":"2020 Nov 17","journal-title":"Trop. Med. Int. Health."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"583-588","DOI":"10.1016\/j.pt.2006.09.011","article-title":"The future of Chagas disease control.","volume":"22","author":"C Schofield","year":"2006 Dec","journal-title":"Trends Parasitol."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.lana.2021.100044","article-title":"The evolution of Brazilian Health Sciences and the present situation.","volume":"3","author":"A Carvalho","year":"2021 Nov","journal-title":"Lancet Reg. Heal. - Am."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"59-88","DOI":"10.1016\/B978-0-12-801029-7.00004-6","author":"A Moncayo","year":"2017","journal-title":"American Trypanosomiasis Chagas Disease."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e000011","DOI":"10.1136\/bmjgh-2015-000011","article-title":"Global Surgery 2030: a roadmap for high income country actors.","volume":"1","author":"J Ng-Kamstra","year":"2016 Apr","journal-title":"BMJ Glob. Health."},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00023-19","article-title":"Chagas Disease in the United States: a Public Health Approach.","volume":"33","author":"C Bern","year":"2019 Dec 18","journal-title":"Clin. Microbiol. Rev."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and Treatment of Chagas Disease in the United States.","volume":"298","author":"C Bern","year":"2007 Nov 14","journal-title":"JAMA."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"22-27","DOI":"10.1016\/j.actatropica.2009.07.019","article-title":"Chagas disease in Spain, the United States and other non-endemic countries.","volume":"115","author":"J Gascon","year":"2010 Jul","journal-title":"Acta Trop."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"263-274","DOI":"10.1007\/s11908-012-0259-3","article-title":"Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment.","volume":"14","author":"J P\u00e9rez-Molina","year":"2012 Jun 3","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e379-e380","DOI":"10.1016\/S2214-109X(17)30090-6","article-title":"Chagas disease in non-endemic countries.","volume":"5","author":"M Castillo-Riquelme","year":"2017 Apr","journal-title":"Lancet Glob. Health."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"368-380","DOI":"10.1002\/jrsm.1533","article-title":"Risk of bias assessment in preclinical literature using natural language processing.","volume":"13","author":"Q Wang","year":"2022 May 5","journal-title":"Res. Synth. Methods."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"4807-4823","DOI":"10.2147\/DDDT.S90208","article-title":"Translational challenges of animal models in Chagas disease drug development: a review.","volume":"9","author":"E Chatelain","year":"2015 Aug","journal-title":"Drug Des. Devel. Ther."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"471-479","DOI":"10.1002\/ddr.20454","article-title":"Clinical aspects of Chagas disease and implications for novel therapies.","volume":"72","author":"C Menezes","year":"2011 Sep 20","journal-title":"Drug Dev. Res."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"835-841","DOI":"10.2174\/1389450121999201124122643","article-title":"New Approaches for the Treatment of Chagas Disease.","volume":"22","author":"R Pandey","year":"2021 May","journal-title":"Curr. Drug Targets."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"939-947","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.","volume":"69","author":"C Morillo","year":"2017 Feb","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"395-403","DOI":"10.1016\/S1473-3099(23)00651-5","article-title":"Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial.","volume":"24","author":"M Pinazo","year":"2024 Jan","journal-title":"Lancet Infect. Dis."},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02655\/full","article-title":"Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites.","volume":"9","author":"S Varikuti","year":"2018 Nov 30","journal-title":"Front. Microbiol."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"289-298","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects.","volume":"6","author":"S Patterson","year":"2014 Jun 30","journal-title":"Trends Parasitol."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1736-1745","DOI":"10.1016\/j.bcp.2010.02.009","article-title":"Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved?","volume":"79","author":"M Boiani","year":"2010 Jun","journal-title":"Biochem. Pharmacol."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"126-130","DOI":"10.1128\/AAC.49.1.126-130.2005","article-title":"Buthionine Sulfoximine Increases the Toxicity of Nifurtimox and Benznidazole to Trypanosoma cruzi.","volume":"49","author":"M Faundez","year":"2005 Jan","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1-26","DOI":"10.1007\/978-3-030-44054-1_1","author":"R Oliveira","year":"2020","journal-title":"Chagas Disease."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"762-775","DOI":"10.1016\/B978-0-323-55512-8.00103-4","author":"R L\u00f3pez-V\u00e9lez","year":"2020","journal-title":"Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases."},{"key":"ref90","first-page":"65-87","article-title":"Targeting Trypanosoma cruzi Sterol 14\u03b1-Demethylase (CYP51).","author":"G Lepesheva","year":"2011"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1-19","DOI":"10.1155\/2015\/324915","article-title":"The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi Infection.","volume":"2015","author":"C Morais","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"4151-4163","DOI":"10.1128\/AAC.00070-13","article-title":"In Vitro and in vivo Studies of the Antiparasitic Activity of Sterol 14\u03b1-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi.","volume":"57","author":"M Soeiro","year":"2013 Sep","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02098-16","article-title":"Antitrypanosomal Activity of Sterol 14\u03b1-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.","volume":"61","author":"F Guedes-da-Silva","year":"2017 Apr","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"10910-10921","DOI":"10.1021\/acs.jmedchem.8b01671","article-title":"Sterol 14\u03b1-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.","volume":"61","author":"L Friggeri","year":"2018 Dec 13","journal-title":"J. Med. Chem."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1017\/S1462399410001560","article-title":"The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease.","volume":"12","author":"C Junqueira","year":"2010 Sep 15","journal-title":"Expert Rev. Mol. Med."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"269-283","DOI":"10.1017\/S0031182018001506","article-title":"A systematic review of the Trypanosoma cruzi genetic heterogeneity, host immune response and genetic factors as plausible drivers of chronic chagasic cardiomyopathy.","volume":"146","author":"P Jim\u00e9nez","year":"2019 Mar 13","journal-title":"Parasitology."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"8893","DOI":"10.1038\/s41598-017-08086-8","article-title":"A multi-parametric analysis of Trypanosoma cruzi infection: common pathophysiologic patterns beyond extreme heterogeneity of host responses.","volume":"7","author":"J Santi-Rocca","year":"2017 Aug 21","journal-title":"Sci. Rep."},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00918\/full","article-title":"An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of Trypanosoma cruzi That Depicts the Multifunctionality and Dysfunctionality of T Cells.","volume":"10","author":"J Mateus","year":"2019 Apr 26","journal-title":"Front. Immunol."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"824-838","DOI":"10.1016\/j.ejmech.2018.06.040","article-title":"Current advances in drug discovery for Chagas disease.","volume":"155","author":"C Scarim","year":"2018 Jul","journal-title":"Eur. J. Med. Chem."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"733-737","DOI":"10.1016\/j.ijantimicag.2007.01.014","article-title":"Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy.","volume":"29","author":"J Bustamante","year":"2007 Jun 9","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"32-50","DOI":"10.1016\/j.actatropica.2015.05.029","article-title":"Reservoir host competence and the role of domestic and commensal hosts in the transmission of Trypanosoma cruzi.","volume":"151","author":"R G\u00fcrtler","year":"2015 Nov","journal-title":"Acta Trop."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"9-17","DOI":"10.1016\/S0001-706X(02)00139-0","article-title":"The dog as model for chemotherapy of the Chagas\u2019 disease.","volume":"84","author":"P Guedes","year":"2002 Oct","journal-title":"Acta Trop."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/ani10040648","article-title":"Echocardiographic Findings in Canine Model of Chagas Disease Immunized with DNA Trypanosoma cruzi Genes.","volume":"10","author":"O Rodr\u00edguez-Morales","year":"2020 Apr 9","journal-title":"Animals."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"115-120","DOI":"10.1016\/0020-7519(88)90045-8","article-title":"Experimental Chagas\u2019 disease (Trypanosoma cruzi) in the Brazilian squirrel monkey (Saimiri sciureus): Hematology, cardiology, cellular and humoral immune responses.","volume":"18","author":"O Pung","year":"1988 Feb","journal-title":"Int. J. Parasitol."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"63-69","DOI":"10.1016\/0035-9203(74)90254-5","article-title":"Experimental Trypanosoma cruzi infection in rhesus monkeys\u2014The acute phase.","volume":"68","author":"S Seah","year":"1974 Jan","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"269-72","DOI":"10.1590\/S0074-02761999000700045","article-title":"Mouse as a model for Chagas disease: does mouse represent a good model for Chagas disease?","volume":"94","author":"S Costa","year":"1999 Sep","journal-title":"Mem. Inst. Oswaldo Cruz."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"175-182","DOI":"10.1038\/nature25753","article-title":"Meta-analysis and the science of research synthesis.","volume":"555","author":"J Gurevitch","year":"2018 Mar 8","journal-title":"Nature."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"253-260","DOI":"10.2215\/CJN.01430307","article-title":"Systematic Review and Meta-analysis: When One Study Is Just not Enough.","volume":"3","author":"A Garg","year":"2008 Jan","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"64-126","DOI":"10.35566\/jbds\/v3n2\/wang","article-title":"Conducting Meta-analyses of Proportions in R.","volume":"3","author":"N Wang","year":"2023","journal-title":"J. Behav. Data Sci."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"4653-4661","DOI":"10.1128\/AAC.00520-15","article-title":"Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.","volume":"59","author":"A Francisco","year":"2015 Aug","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref111","doi-asserted-by":"publisher","first-page":"36-43","DOI":"10.1177\/1087057114552623","article-title":"A New Experimental Model for Assessing Drug Efficacy against Trypanosoma cruzi Infection Based on Highly Sensitive In Vivo Imaging.","volume":"20","author":"M Lewis","year":"2014 Jan","journal-title":"J. Biomol. Screen."},{"key":"ref112","doi-asserted-by":"publisher","first-page":"91-101","DOI":"10.1016\/j.trre.2010.12.002","article-title":"Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas.","volume":"25","author":"M Pinazo","year":"2011 Jul","journal-title":"Transplant. Rev."},{"key":"ref114","doi-asserted-by":"publisher","first-page":"166-175","DOI":"10.1016\/S0140-6736(13)62227-8","article-title":"Increasing value and reducing waste in research design, conduct, and analysis.","volume":"383","author":"J Ioannidis","year":"2014 Jan","journal-title":"Lancet."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"94-99","DOI":"10.4103\/0976-500X.72351","article-title":"Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research.","volume":"1","author":"C Kilkenny","year":"2010 Dec 1","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43094-020-00047-9","article-title":"Exploring different approaches to improve the success of drug discovery and development projects: a review.","volume":"6","author":"G Kiriiri","year":"2020 Dec 23","journal-title":"Futur. J. Pharm. Sci."},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1659-1680","DOI":"10.1111\/cts.13066","article-title":"3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.","volume":"14","author":"H Wang","year":"2021 Sep 16","journal-title":"Clin. Transl. Sci."},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1177\/15347346241236385","article-title":"A Simple Guide to Randomized Controlled Trials.","author":"A Liakos","year":"2024 Feb 28","journal-title":"Int. J. Low Extrem. Wounds."},{"key":"ref119","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13561-021-00302-6","article-title":"Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - A scenario analysis.","volume":"11","author":"J Mahlich","year":"2021 Dec 16","journal-title":"Heal. Econ. Rev."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1243-1269","DOI":"10.1007\/s40273-021-01065-y","article-title":"How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.","volume":"39","author":"M Schlander","year":"2021 Nov 9","journal-title":"Pharmacoeconomics."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"164-176","DOI":"10.1001\/jama.2019.20288","article-title":"FDA Approval and Regulation of Pharmaceuticals, 1983-2018.","volume":"323","author":"J Darrow","year":"2020 Jan 14","journal-title":"JAMA."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"e0255226","DOI":"10.1371\/journal.pone.0255226","article-title":"Social determinants in the access to health care for Chagas disease: A qualitative research on family life in the \u201cValle Alto\u201d of Cochabamba, Bolivia.","volume":"16","author":"I Jimeno","year":"2021 Aug 12","journal-title":"PLoS One."},{"key":"ref123","doi-asserted-by":"publisher","first-page":"531-537","DOI":"10.1080\/17460441.2020.1736550","article-title":"Partnerships for better neglected disease drug discovery and development: how have we fared?","volume":"15","author":"T Sunyoto","year":"2020 May 3","journal-title":"Expert Opin. Drug Discov."},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.26240111","article-title":"Supplementary figure of results from systematic reviews and meta-analyses.","author":"L Machaca-Luque","year":"2024","journal-title":"Figshare."},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.28635869","article-title":"Supplementary tables of results from systematic reviews and meta-analyses.","author":"L Machaca-Luque","year":"2024","journal-title":"Figshare."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/13-885\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-885\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-885\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:55:09Z","timestamp":1748454909000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/13-885\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":123,"URL":"https:\/\/doi.org\/10.12688\/f1000research.150723.3","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.150723.2","asserted-by":"subject"},{"id-type":"doi","id":"10.12688\/f1000research.150723.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.182003.r385243","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.182003.r385243","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/13-885\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.182003.r385243, Juan Carlos Gabaldon, Barcelona Institute for Global Health, Universitat de Barcelona, Barcelona, Catalonia, 28 May 2025, version 3, indexed","URL":"https:\/\/f1000research.com\/articles\/13-885\/v3#referee-response-385243","order":0,"name":"referee-response-385243","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.179980.r378071, Andrea Angheben, IRCCS Sacro Cuore Hospital, Negrar, Verona, 05 May 2025, version 2, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/13-885\/v2#referee-response-378071","order":1,"name":"referee-response-378071","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This research was funded by Universidad Cat\u00f3lica de Santa Mar\u00eda (grants 27574-R-2020, and 28048-R-2021). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}